Sunshine Heart to Present at Upcoming Investor Conferences

EDEN PRAIRIE, Minn., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) today announced that the company is scheduled to present a corporate update at the following upcoming investor conferences for the balance of 2013:

  • 2013 Credit Suisse Healthcare Conference

Presentation: Tuesday, November 12, 2013 at 9:30 AM MST at The Phoenician in Scottsdale, Arizona. Breakout session to immediately follow presentation at 10:00 AM MST

Presenting: Jeff Mathiesen, Chief Financial Officer

  • 2013 Canaccord Genuity Medical Technology & Diagnostics Forum

Presentation: Thursday, November 14, 2013 at 3:30 PM EST at the Westin Grand Central in New York, New York

Presenting: Jeff Mathiesen, Chief Financial Officer

  • Barclays Select Series 2013: Growth Conference

Presentation: Tuesday, November 19, 2013 at 8:20 AM EST at 745 7th Ave in New York, New York (Club Room I)

Presenting: Kevin Bassett, Senior Vice President of Technology and Operations

  • Piper Jaffray 25th Annual Healthcare Conference

Presentation: Tuesday, December 3, 2013 at 1:30 PM EST at the New York Palace Hotel in New York, New York (Rutherford Room)

Presenting: Dave Rosa, Chief Executive Officer

  • Oppenheimer 24th Annual Healthcare Conference

Presentation: Wednesday, December 11, 2013 at 2:10 EST at the Crowne Plaza Hotel in New York, New York

Presenting: Jeff Mathiesen, Chief Financial Officer

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility trial, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine® Heart

Sunshine Heart, Inc. is a medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical trial of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal trial. In July 2012 Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with a wholly owned subsidiary in Australia. The Company has been listed on the NASDAQ Capital Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, future clinical trial activities and results including patient enrollment in trials. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical trials do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the European Union and the other risk factors described under the caption "Risk Factors" and elsewhere in our filings with the Securities and Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

CONTACT: For further information, please contact: Media: Laura Forman Blueprint Life Science Group T: +1-415-375-3340 Investor: Jeff Mathiesen Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4200

Source:Sunshine Heart, Inc.